- July 18, 2022
- Newsletter
- 617-430-5616
Menu
ADVERTISEMENT
ADVERTISEMENT
Background
Epidemiology
Anatomy
Pathophysiology
Etiology
Genetics
Prognostic Factors
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Administer 1500mg orally every day
Hydroxyurea can be used along if needed
Dose Adjustments
Renal impairment: No dosage adjustment is necessary
Hepatic impairment:
Mild to moderate: No dosage adjustment necessary (Child A pugh or B)
Severe: Reduce to 1000 mg every day or 900 mg oral suspension orally every day (Child-Pugh C)
CYP3A4 inducers
Avoid administering CYP3A4 inducers in combination, whether they are strong or mild.
Increase dosage to 2500 mg orally once a day for strong CYP3A4 inducers.
Increase to 2,000 mg orally every day for moderate CYP3A4 inducers.
lovotibeglogene autotemcel (FDA Approval Pending)
FDA Approval Pending as one-time gene therapy for sickle cell disease in patients aged ≥12 years
According to response and blood count, the Initial dose of 15 mg/kg orally daily by 2.5 to 5 mg/kg every 12 weeks. Usual dosage: 15 to 30 mg/kg every day. Maximum dose: 35 mg/kg daily
Dose Adjustments
Dosing modifications
Renal impairment:
CrCl less than 60 ml/min: 7.5 mg/kg daily, titrate based on the response
Hepatic impairment: Severe (Child-Pugh score C): Contraindicated
initial dose :
20
mg/kg
Orally
once a day
Increase 5 mg per kg per day every eight weeks depending on the severity <>br
maximum dose: 35 mg/kg per day
The blood counts need to be monitored
<4 years: Safety and efficacy not established
>12 years: Administer 1500mg orally every day
4 to 11 years:
10 to <20 kg: 600mg orally every day
20 to <40kg: 900mg orally every day
≥40kg: 1500mg orally every day
Dose Adjustments
Renal impairment: No dosage adjustment is necessary
Hepatic impairment:
Mild to moderate: No dosage adjustment necessary (Child A pugh or B)
Severe: Reduce to 1000 mg orally every day or 900 mg oral suspension orally every day (Child-Pugh C)
20 kg to <40kg: Reduce the dose to 600mg orally every day
10 kg to <20kg: Reduce the dosage to 300mg orally every day
lovotibeglogene autotemcel (FDA Approval Pending)
FDA Approval Pending as one-time gene therapy for sickle cell disease in patients aged ≥12 years
Future Trends
References
ADVERTISEMENT
Administer 1500mg orally every day
Hydroxyurea can be used along if needed
Dose Adjustments
Renal impairment: No dosage adjustment is necessary
Hepatic impairment:
Mild to moderate: No dosage adjustment necessary (Child A pugh or B)
Severe: Reduce to 1000 mg every day or 900 mg oral suspension orally every day (Child-Pugh C)
CYP3A4 inducers
Avoid administering CYP3A4 inducers in combination, whether they are strong or mild.
Increase dosage to 2500 mg orally once a day for strong CYP3A4 inducers.
Increase to 2,000 mg orally every day for moderate CYP3A4 inducers.
lovotibeglogene autotemcel (FDA Approval Pending)
FDA Approval Pending as one-time gene therapy for sickle cell disease in patients aged ≥12 years
According to response and blood count, the Initial dose of 15 mg/kg orally daily by 2.5 to 5 mg/kg every 12 weeks. Usual dosage: 15 to 30 mg/kg every day. Maximum dose: 35 mg/kg daily
Dose Adjustments
Dosing modifications
Renal impairment:
CrCl less than 60 ml/min: 7.5 mg/kg daily, titrate based on the response
Hepatic impairment: Severe (Child-Pugh score C): Contraindicated
initial dose :
20
mg/kg
Orally
once a day
Increase 5 mg per kg per day every eight weeks depending on the severity <>br
maximum dose: 35 mg/kg per day
The blood counts need to be monitored
<4 years: Safety and efficacy not established
>12 years: Administer 1500mg orally every day
4 to 11 years:
10 to <20 kg: 600mg orally every day
20 to <40kg: 900mg orally every day
≥40kg: 1500mg orally every day
Dose Adjustments
Renal impairment: No dosage adjustment is necessary
Hepatic impairment:
Mild to moderate: No dosage adjustment necessary (Child A pugh or B)
Severe: Reduce to 1000 mg orally every day or 900 mg oral suspension orally every day (Child-Pugh C)
20 kg to <40kg: Reduce the dose to 600mg orally every day
10 kg to <20kg: Reduce the dosage to 300mg orally every day
lovotibeglogene autotemcel (FDA Approval Pending)
FDA Approval Pending as one-time gene therapy for sickle cell disease in patients aged ≥12 years
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.